Ion channels in T lymphocytes: An update on facts, mechanisms and therapeutic targeting in autoimmune diseases

Immunology Letters

Volumn 130, Issue 1-2, 2010, Pages 19-25

  Varga, Zoltan ^a   Hajdu, Peter ^a   Panyi, Gyorgy ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Immunological synapse; Immunosuppression; Ion channel; T cell activation

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL; CYCLOSPORIN A; ION CHANNEL; PAP 1; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.3; SHK TOXIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHANNEL GATING; DELAYED HYPERSENSITIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STABILITY; DRUG TARGETING; EFFECTOR CELL; HUMAN; IMMUNOLOGICAL SYNAPSE; INSULIN DEPENDENT DIABETES MELLITUS; INTRACELLULAR SIGNALING; KIDNEY GRAFT REJECTION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN ALLERGY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE INJURY;

ANIMALS; AUTOIMMUNE DISEASES; CALCIUM; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOLOGICAL SYNAPSES; ION CHANNELS; KV1.3 POTASSIUM CHANNEL; LYMPHOCYTE ACTIVATION; MEMBRANE TRANSPORT MODULATORS; T-LYMPHOCYTES;

EID: 77950945397     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2009.12.015     Document Type: Review

References (74)

1. + channels in human T lymphocytes: a role in mitogenesis?. Nature 1984, 307:465-468.
2. Matteson D.R., Deutsch C. K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. Nature 1984, 307:468-471.
3. Grissmer S., Nguyen A.N., Cahalan M.D. Calcium-activated potassium channels in resting and activated human T lymphocytes. Expression levels, calcium dependence, ion selectivity, and pharmacology. J Gen Physiol 1993, 102:601-630.
4. Fanger C.M., Ghanshani S., Logsdon N.J., Rauer H., Kalman K., Zhou J., et al. Calmodulin mediates calcium-dependent activation of the intermediate conductance KCa channel, IKCa1. J Biol Chem 1999, 274:5746-5754.
5. Cahalan M.D., Chandy K.G. The functional network of ion channels in T lymphocytes. Immunol Rev 2009, 231:59-87.
6. 2+ stores. Proc Natl Acad Sci USA 1993, 90:6295-6299.
7. Partiseti M., Le Deist F., Hivroz C., Fischer A., Korn H., Choquet D. The calcium current activated by T cell receptor and store depletion in human lymphocytes is absent in a primary immunodeficiency. J Biol Chem 1994, 269:32327-32335.
8. 2+ store to the plasma membrane. Nature 2005, 437:902-905.
9. 2+ influx. Curr Biol 2005, 15:1235-1241.
10. Feske S., Gwack Y., Prakriya M., Srikanth S., Puppel S.H., Tanasa B., et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 2006, 441:179-185.
11. 2+ entry. Science 2006, 312:1220-1223.
12. Penna A., Demuro A., Yeromin A.V., Zhang S.L., Safrina O., Parker I., et al. The CRAC channel consists of a tetramer formed by Stim-induced dimerization of Orai dimers. Nature 2008, 456:116-120.
13. + channel in effector memory T cells as new target for MS. J Clin Invest 2003, 111:1703-1713.
14. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004, 22:745-763.
15. Beeton C., Wulff H., Standifer N.E., Azam P., Mullen K.M., Pennington M.W., et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 2006, 103:17414-17419.
16. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 2001, 98:13942-13947.
17. Ghanshani S., Wulff H., Miller M.J., Rohm H., Neben A., Gutman G.A., et al. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem 2000, 275:37137-37149.
18. Rus H., Pardo C.A., Hu L., Darrah E., Cudrici C., Niculescu T., et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci USA 2005, 102:11094-11099.
19. + channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol 2001, 166:936-944.
20. Beeton C., Pennington M.W., Wulff H., Singh S., Nugent D., Crossley G., et al. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol 2005, 67:1369-1381.
21. Pennington M.W., Beeton C., Galea C.A., Smith B.J., Chi V., Monaghan K.P., et al. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol Pharmacol 2009, 75:762-773.
22. Azam P., Sankaranarayanan A., Homerick D., Griffey S., Wulff H. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol 2007, 127:1419-1429.
23. Grgic I., Wulff H., Eichler I., Flothmann C., Kohler R., Hoyer J. Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant Proc 2009, 41:2601-2606.
24. Koo G.C., Blake J.T., Talento A., Nguyen M., Lin S., Sirotina A., et al. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol 1997, 158:5120-5128.
25. Valverde P., Kawai T., Taubman M.A. Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. J Bone Miner Res 2004, 19:155-164.
26. + channel blockers: novel tools to inhibit T cell activation leading to specific immunosuppression. Curr Pharm Des 2006, 12:2199-2220.
27. + channels as targets for specific immunomodulation. Trends Pharmacol Sci 2004, 25:280-289.
28. Vennekamp J., Wulff H., Beeton C., Calabresi P.A., Grissmer S., Hansel W., et al. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol 2004, 65:1364-1374.
29. + channel: peptide and channel residues mediating molecular recognition. Neuron 1994, 12:1377-1388.
30. Corzo G., Papp F., Varga Z., Barraza O., Espino-Solis P.G., Rodriguez de la Vega R.C., et al. A selective blocker of Kv1.2 and Kv1.3 potassium channels from the venom of the scorpion Centruroides suffusus suffusus. Biochem Pharmacol 2008, 76:1142-1154.
31. + channel revealed by the NMR-derived structures of scorpion toxins. Neuron 1995, 15:1169-1181.
32. + conduction and selectivity. Science 1998, 280:69-77.
33. + channels. J Biol Chem 2000, 275:1201-1208.
34. + channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochem J 2005, 385:95-104.
35. Castaneda O., Sotolongo V., Amor A.M., Stocklin R., Anderson A.J., Harvey A.L., et al. Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus. Toxicon 1995, 33:603-613.
36. Kalman K., Pennington M.W., Lanigan M.D., Nguyen A., Rauer H., Mahnir V., et al. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J Biol Chem 1998, 273:32697-32707.
37. Yan L., Herrington J., Goldberg E., Dulski P.M., Bugianesi R.M., Slaughter R.S., et al. Stichodactyla helianthus peptide, a pharmacological tool for studying Kv3.2 channels. Mol Pharmacol 2005, 67:1513-1521.
38. Middleton R.E., Sanchez M., Linde A.R., Bugianesi R.M., Dai G., Felix J.P., et al. Substitution of a single residue in Stichodactyla helianthus peptide, ShK-Dap22, reveals a novel pharmacological profile. Biochemistry 2003, 42:13698-13707.
39. Beeton C., Wulff H., Singh S., Botsko S., Crossley G., Gutman G.A., et al. A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. J Biol Chem 2003, 278:9928-9937.
40. Nguyen A.N., Kath J.C., Hanson D.C., Biggers M.S., Cannif P.C., Donovan C.B., et al. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation. Mol Pharmacol 1996, 50:1672-1679.
41. Koo G.C., Blake J.T., Shah K., Staruch M.J., Dumont F., Wunderler D., et al. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell Immunol 1999, 197:99-107.
42. Hanson D.C., Nguyen A., Mather R.J., Rauer H., Koch K., Burgess L.E., et al. UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation. Br J Pharmacol 1999, 126:1707-1716.
43. Schmitz A., Sankaranarayanan A., Azam P., Schmidt-Lassen K., Homerick D., Hansel W., et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol 2005, 68:1254-1270.
44. Panyi G., Vamosi G., Bacso Z., Bagdany M., Bodnar A., Varga Z., et al. Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. Proc Natl Acad Sci USA 2004, 101:1285-1290.
45. Panyi G., Bagdany M., Bodnar A., Vamosi G., Szentesi G., Jenei A., et al. Colocalization and nonrandom distribution of Kv1.3 potassium channels and CD3 molecules in the plasma membrane of human T lymphocytes. Proc Natl Acad Sci USA 2003, 100:2592-2597.
46. Lioudyno M.I., Kozak J.A., Penna A., Safrina O., Zhang S.L., Sen D., et al. Orai1 and STIM1 move to the immunological synapse and are up-regulated during T cell activation. Proc Natl Acad Sci USA 2008, 105:2011-2016.
47. Nicolaou S.A., Szigligeti P., Neumeier L., Lee S.M., Duncan H.J., Kant S.K., et al. Altered dynamics of Kv1.3 channel compartmentalization in the immunological synapse in systemic lupus erythematosus. J Immunol 2007, 179:346-356.
48. + channel KCa3.1 compartmentalizes in the immunological synapse of human T lymphocytes. Am J Physiol Cell Physiol 2007, 292:C1431-C1439.
49. van der Merwe P.A. Formation and function of the immunological synapse. Curr Opin Immunol 2002, 14:293-298.
50. Bromley S.K., Burack W.R., Johnson K.G., Somersalo K., Sims T.N., Sumen C., et al. The immunological synapse. Annu Rev Immunol 2001, 19:375-396.
51. Chung I., Schlichter L.C. Native Kv1.3 channels are upregulated by protein kinase C. J Membr Biol 1997, 156:73-85.
52. Chung I., Schlichter L.C. Regulation of native Kv1.3 channels by cAMP-dependent protein phosphorylation. Am J Physiol 1997, 273:C622-C633.
53. Holmes T.C., Fadool D.A., Levitan I.B. Tyrosine phosphorylation of the Kv1.3 potassium channel. J Neurosci 1996, 16:1581-1590.
54. Bowlby M.R., Fadool D.A., Holmes T.C., Levitan I.B. Modulation of the Kv1.3 potassium channel by receptor tyrosine kinases. J Gen Physiol 1997, 110:601-610.
55. lck tyrosine kinase and Shaker type Kv1.3 potassium channel in T lymphocytes. J Biol Chem 1997, 272:26899-26904.
56. Gong J., Xu J., Bezanilla M., van Huizen R., Derin R., Li M. Differential stimulation of PKC phosphorylation of potassium channels by ZIP1 and ZIP2. Science 1999, 285:1565-1569.
57. Marks D.R., Fadool D.A. Post-synaptic density perturbs insulin-induced Kv1.3 channel modulation via a clustering mechanism involving the SH3 domain. J Neurochem 2007, 103:1608-1627.
58. Xavier R., Rabizadeh S., Ishiguro K., Andre N., Ortiz J.B., Wachtel H., et al. Discs large (Dlg1) complexes in lymphocyte activation. J Cell Biol 2004, 166:173-178.
59. Round J.L., Tomassian T., Zhang M., Patel V., Schoenberger S.P., Miceli M.C. Dlgh1 coordinates actin polymerization, synaptic T cell receptor and lipid raft aggregation, and effector function in T cells. J Exp Med 2005, 201:419-430.
60. Vicente R., Escalada A., Soler C., Grande M., Celada A., Tamkun M.M., et al. Pattern of Kvβ subunit expression in macrophages depends upon proliferation and the mode of activation. J Immunol 2005, 174:4736-4744.
61. Robbins J.R., Lee S.M., Filipovich A.H., Szigligeti P., Neumeier L., Petrovic M., et al. Hypoxia modulates early events in T cell receptor-mediated activation in human T lymphocytes via Kv1.3 channels. J Physiol 2005, 564:131-143.
62. 2 sensitivity of Kv1.3 channels. J Physiol 2006, 573:357-370.
63. lck regulates specificity of its Src homology 2 domain. Proc Natl Acad Sci USA 1995, 92:5778-5782.
64. lck and its regulation by phosphorylation of Ser-59 in the lck unique N-terminal region. Proc Natl Acad Sci USA 1995, 92:12338-12342.
65. lck, belongs to a new class of ubiquitin-binding proteins. J Biol Chem 1996, 271:20235-20237.
66. Diradourian C., Le May C., Cauzac M., Girard J., Burnol A.F., Pegorier J.P. Involvement of ZIP/p62 in the regulation of PPARα transcriptional activity by p38-MAPK. Biochim Biophys Acta 2008, 1781:239-244.
67. Kim J.Y., Ozato K. The sequestosome 1/p62 attenuates cytokine gene expression in activated macrophages by inhibiting IFN regulatory factor 8 and TNF receptor-associated factor 6/NF-κB activity. J Immunol 2009, 182:2131-2140.
68. Toth A., Szilagyi O., Krasznai Z., Panyi G., Hajdu P. Functional consequences of Kv1.3 ion channel rearrangement into the immunological synapse. Immunol Lett 2009, 125:15-21.
69. Hajdu P., Varga Z., Pieri C., Panyi G., Gaspar R. Cholesterol modifies the gating of Kv1.3 in human T lymphocytes. Pflugers Arch 2003, 445:674-682.
70. CRAC due to local calcium feedback. J Gen Physiol 1995, 105:209-226.
71. Zweifach A., Lewis R.S. Slow calcium-dependent inactivation of depletion-activated calcium current. Store-dependent and -independent mechanisms. J Biol Chem 1995, 270:14445-14451.
72. 2+ overload. J Cell Sci 2008, 121:3133-3139.
73. Nicolaou S.A., Neumeier L., Steckly A., Kucher V., Takimoto K., Conforti L. Localization of Kv1.3 channels in the immunological synapse modulates the calcium response to antigen stimulation in T lymphocytes. J Immunol 2009, 183:6296-6302.
74. Krummel M.F., Sjaastad M.D., Wulfing C., Davis M.M. Differential clustering of CD4 and CD3ζ during T cell recognition. Science 2000, 289:1349-1352.